Alentis Therapeutics Closes $105 Million Series C Funding to

Proceeds will fund:- Clinical programs ALE.F02 and ALE.C04 – two first-in-class anti-Claudin-1 (CLDN1) antibodies for organ fibrosis and CLDN1 positive tumors- The platform to engineer CLDN1 antibody drug conjugates (ADC) and bi-specific antibodiesBASEL, Switzerland--(BUSINESS WIRE)--Alentis Therapeutics (“Alentis”)...

Related Keywords

Singapore , San Francisco , California , United States , Shanghai , China , Copenhagen , Køavn , Denmark , France , Switzerland , Paris , France General , Boston , Massachusetts , London , City Of , United Kingdom , Naveed Siddiqi , Roberto Iacone , Nathalie Graf Tschupp , Pureos Bioventures , Opatrick Wilson , French National Institute Of Health Inserm , Novo Nordisk Foundation , University Of Strasbourg , Novo Group , Novo Nordisk , Novo Holdings , Alentis Therapeutics , Jeito Capital , Holdings Senior Partner , Alentis Therapeutic Board , Venture Investments , Thomas Baumert , French National Institute , Private Equity , Life Science Investments , Seed Investments , Growth Investments , Capital Investments ,